Background. Patients with chronic hepatitis B virus (HBV) may experience spontaneous biochemical flares of liver disease activity. This study aimed to determine (i) the prevalence of prior and possible acute hepatitis E virus (HEV) infection among persons with chronic HBV and (ii) whether HEV infection is associated with liver disease flares among persons with chronic HBV.
Hepatitis E virus (HEV) is endemic in many developing countries, where it is transmitted through the fecal-oral route and is an important cause of acute hepatitis, fulminant hepatic failure, and acute-on-chronic liver disease [1] . In contrast, large-scale outbreaks are rare in developed countries due to better infrastructure, water supply, and sanitation. However, clusters of disease have been reported in areas of low endemicity that are not associated with travel to areas of high endemicity but instead are associated with zoonotic transmission [2] .
There are at least 5 genotypes of HEV (Orthohepevirus A) that infect humans and have different epidemiological features. Genotypes 1 and 2 are restricted to humans and are associated with fecal-oral transmitted epidemics in developing countries.
Seroprevalence is estimated to range from 15% to 25% in Africa and parts of Asia [3] . In the United States, infection with genotypes 1 and 2 is typically found only in persons who have recently traveled to countries of high endemicity [4] , including Mexico and Central America. Genotypes 3 and 4 are associated with sporadic cases of acute hepatitis in humans and are commonly found in domestic pigs, wild boar, and deer. Genotype 3 is found worldwide, whereas genotype 4 is found mainly in eastern Asia. Zoonotic transmission of genotypes 3 or 4 can occur through consumption of undercooked pig organ meat [5] , deer meat [6] , or contact with infected swine [7, 8] . Additionally, a recent case report described zoonotic transmission of genotype 7 HEV linked to consumption of camel-derived food products [9] .
In Western Europe, genotype 3 HEV infection is increasingly recognized as an emerging infection [10] , whose transmission is thought to be primarily foodborne [11] . HEV can also be transmitted by blood transfusion, but this is rare [12] . Although typically an acute, self-limiting infection, HEV can establish persistent infection among immunosuppressed persons such as transplant recipients [13] . Persistent genotype 3 HEV infections have been detected in Europe and the United States in transplant recipients who received blood products from infected but asymptomatic donors [13] .
The extent of autochthonous genotype 3 HEV transmission in the United States is unclear, as surveillance efforts have been limited, but it may have been underestimated because, in contrast to genotypes 1 and 2, viremic persons with no comorbidities can be asymptomatic [10, 14, 15] . Furthermore, genotype 3 HEV infections among persons with underlying chronic liver disease may have been missed as clinical features of acute hepatitis E are indistinguishable from acute episodes of chronic hepatotropic virus infections or drug-induced liver injury [16] . In previously asymptomatic persons with chronic hepatitis B virus (HBV) infection, we hypothesize that co-infection with HEV may be responsible for acute exacerbation of liver disease.
The Hepatitis B Research Network (HBRN) is a National Institutes of Health-funded cooperative network that includes 21 clinical sites that recruited adult participants into an observational cohort study from diverse regions and populations in the United States and Canada to better understand the natural history of chronic hepatitis B [17] . This ancillary study aimed to examine (i) the seroprevalence of anti-HEV among adults with chronic HBV and associated demographic and clinical features and (ii) whether acute HEV infection is associated with the occurrence of serum ALT flares among adults with chronic HBV enrolled in the HBRN Adult Cohort Study.
METHODS

Study Design and Sample Selection
Details of the HBRN Cohort Study protocol and characteristics of the adult participants have been described previously [17] . Institutional review board approval was obtained from all clinical sites. All participants provided written informed consent.
Determining Seroprevalence of Anti-HEV in the HBRN Adult Cohort
As of November 21, 2016 November 21, , 1991 HBsAg+ participants were enrolled in the HBRN Adult Cohort Study (Figure 1 ). Of these, 1351 had chronic HBV, were not in targeted enrollment groups (eg, acute, pregnant, hepatitis D virus [HDV]+, potentially eligible for 1 of the clinical trials), and had a serum sample at, or within 48 weeks of, study entry. To obtain estimates of the prevalence of HEV viremia and anti-HEV seropositivity, a random sample of 600 participants was selected and tested for anti-HEV IgG and IgM. Most of the participants in the random sample of 600 were noncirrhotic on the sample date: 8 participants had cirrhosis before the sample date, 1 had date of onset of cirrhosis on the sample date, and 1 had date of onset of cirrhosis 4 days after the sample date. The next closest cirrhosis onset was 15 weeks after the sample date.
Association of Anti-HEV Positivity With Unexplained Liver Disease Flares Among Adults With Chronic HBV
At or after enrollment, there were 122 adjudicated ALT flare events, defined as ALT ≥10 times the upper limit of normal (ULN; female ≥200 U/L, male ≥300 U/L) among the 1991 participants ( Figure 2 ). Adjudication included both the date the flare began and its etiology. For the aim (ii) analyses, we excluded 24 flare events adjudicated as having known etiology (withdrawal of antiviral or immunosuppressive therapy [n = 11], HDV coinfection [n = 2], immune tolerant to immune active transition [n = 3], antiviral or drug-induced liver injury [n = 3], pregnancy or miscarriage [n = 2], and HBV related but cannot determine [n = 3]). The remaining 98 flare events occurred among 88 individuals. Other exclusions were 1 flare that occurred when the participant was receiving peginterferon and 15 for whom no serum was available between 6 weeks before and 12 weeks after the adjudicated flare onset date. In the 10 participants who had more than 1 flare event after these exclusions, only the first was included. Thus, 72 flares occurring among 72 participants are included in these analyses. Of these 72 flares, 5 flare cases had cirrhosis before the sample date (1 of whom was also in the random sample to estimate prevalence), 1 had date of onset of cirrhosis 3 weeks after the sample date, and the 1 furthest from the sample date had date of onset of cirrhosis 7 weeks after the sample date.
To determine whether anti-HEV positivity was associated with flare, the 72 cases with at-flare serum were compared with 288 nonflare controls who were not receiving peginterferon and not pregnant from the aim (i) sample. Matching (1 case to 4 controls) was by propensity of being a flare according to sex, age, place of birth, and HBeAg status.
Postflare serum samples >12 weeks and ≤60 weeks after adjudicated date of flare onset were available for 51/72 (71%) flare cases. Eligible postflare controls were identified by nonflare participants who were not receiving peginterferon and not pregnant from the aim (i) and also had a subsequent serum sample. Similar to at-flare, 51 postflare cases were 1:4 matched to 204 postflare controls. The propensity score included time between samples and sex, age, place of birth, and HBeAg status. Finally, to test whether anti-HEV positivity differed over time, preflare was compared with at-flare (n = 49) and postflare (n = 35), and at-flare was compared with postflare (n = 51). No participants decompensated in the time between preflare and postflare sample for this study.
Enzyme-Linked Immunosorbent Assays for Anti-HEV IgM and IgG
Serum samples were tested for anti-HEV IgM and IgG by enzyme-linked immunosorbent assay (ELISA). Commercial ELISA kits for the detection of anti-HEV IgM and IgG in human sera were purchased from Wantai (Beijing, China). Each sample was tested in duplicate. Assays were performed according to the manufacturer's instructions, and absorbance at 450 nm was measured using a Synergy Neo2 plate reader (Biotek, Winooski, VT). For those samples that tested positive for anti-HEV IgM, longitudinal analyses were performed to authenticate the initial test result.
RNA Extraction and Quantitative Reverse Transcription Polymerase Chain Reaction Detection of HEV RNA
RNA was extracted from 200-µL serum samples using the ZR-96 Viral RNA Kit (Zymo Research, Irvine, CA). Purified RNA was eluted into 15 µL of RNase-free moleculargrade water. HEV RNA was measured using a previously validated Taqman reverse transcription polymerase chain reaction (RT-PCR) assay with primers and probe targeting a region in the viral ORF3 region that is highly conserved between genotypes [18, 19] . RNA was quantified by comparison with a standard curve based on serial dilutions of genotype 3 HEV Kernow C1 (p6) genomic RNA that were generated by in vitro transcription from a cDNA clone [20] . The standard curve was compared with the World Health Organization international standard for HEV RNA (code number 6329/10) [21] to calculate a limit of detection for the assay of 75 IU. Multiple logistic regression models were fit stepwise and used to examine the independent (adjusted) associations between seroprevalence and demographic and clinical characteristics. The criterion for both entry and removal from the models was a P value ≤0.05. The results are presented as odds ratios (ORs), 95% confidence intervals (CIs), and P values.
Association of Anti-HEV Positivity With Liver Disease Flares Among Persons With Chronic HBV
The odds of having an ALT flare were compared between participants who were anti-HEV positive and those who were anti-HEV negative using conditional logistic regression to account for the propensity score matching of nonflare controls to flare cases, both at time of flare and postflare. To determine whether flares were associated with seroconversion from anti-HEV negative to positive, McNemar's test was used to test whether seroprevalence of anti-HEV changed pre-vs at-, prevs post-, and at-vs postflare. SAS 9.4 and R 3.4.2 were used for statistical analysis and graphical displays.
RESULTS
Prevalence of HEV Infection in the HBRN Adult Cohort
Among the 600 randomly selected study participants from the HBRN adult cohort, the median age was 42 years, 50.7% were female, 72.5% were Asian, and 19.4% were US or Canada born ( Table 1) . Seroprevalence of anti-HEV+, defined as either anti-HEV IgM positive or anti-HEV IgG positive, was 29%. There were significant differences in anti-HEV prevalence by age (higher prevalence in older participants), males (Table 2) , 71.0% were anti-HEV IgG and IgM negative, 27.3% (n = 164) were anti-HEV IgG (+) only, 0.5% (n = 3) were IgM (+) only, and 1.2% (n = 7) were both IgG (+) and IgM (+). Therefore, the seroprevalence of anti-HEV IgG and IgM was 28.5% (95% CI, 24.9%-32.3%) and 1.7% (95% CI, 0.8%-3.0%), respectively. Median ALT for the 10 anti-HEV IgM+ participants (range) was 27.5 (9-76) U/L.
HEV seroprevalence was examined by geographical region based upon site of enrollment (Supplementary Table 1 ). HEV seroprevalence among participants from the Canadian site was the highest (42%), followed by sites in the US-West (37%), US-Midwest (26%), US-Southwest (23%), US-Southeast (19%), and US-Northeast (18%). Geographical region was strongly associated with the 2 categories of race (Asian vs non-Asian: chisquare test P < .0001): 89% of the participants at the sites in the US-West were Asian, and 85% were Asian at the Canadian site, compared with 56% at sites in the US-Southeast and 58% at sites in the US-Midwest. Thus, in the multivariable model, race (Asian/non-Asian) was used, not region.
In the multivariable (adjusted) logistic regression model, characteristics significantly and independently (P < .05) associated with higher seroprevalence of HEV were older age, male, Asian race, less education, and positive HBeAg (Table 3) . Although those who migrated to the United States or Canada more than 20 years ago did not have a significantly different seroprevalence of HEV than those born in the United States or Canada, more recent immigrants had significantly higher seroprevalence than those born in the United States or Canada.
The association of education with HEV seroprevalence varies by race (P value for race × education interaction = 0.046). Among participants with less than a Bachelor's degree, Asians had 2.9 times higher odds of HEV seroprevalence than nonAsians, whereas the odds of HEV seroprevalence were similar between Asians and non-Asians among those who had at least a Bachelor's degree (Table 3) .
Longitudinal Analyses of Sera From Anti-HEV IgM-Positive Subjects
To further authenticate the 10 anti-HEV IgM-positive subjects, archival sera from before and after the initial positive result were assayed for anti-IgM and IgG (Figure 3 ). Only 4/10 subjects ( Figure 3A-D) were confirmed as recent infections based on anti-HEV IgM and IgG kinetic characteristics of the convalescence phase of acute HEV (anti-HEV IgM positive but declining, anti-HEV IgG increasing). Of these 4 subjects, only 1 (Figure 3 D) had increased ALT around the time of seroconversion. The remaining 6 subjects were unclear or unconfirmed. The only additional sample for subject J was from 184 weeks later, which also tested positive for anti-HEV IgM but was negative for IgG. This case could either represent anti-HEV IgM false positives or mild, acute infections that were not accompanied by development of HEV-specific IgG. In summary, using highly stringent criteria for recent infection based on longitudinal analyses (anti-HEV IgM positive but declining with anti-HEV IgG increasing over time), the prevalence of recent HEV infection was 0.7% (4/600 samples; 95% CI, 0.2%-1.7%).
Testing Whether Anti-HEV Positivity Is Associated With Liver Disease Flares Among Persons With Chronic HBV
The etiologies of the 72 flare cases included spontaneous viral reactivation (n = 32, 44.4%), unsuccessful or spontaneous immune clearance (n = 21, 29.2%), no changes in HBV DNA (n = 11, 15.3%), and other or unknown (n = 8, 11.1%) ( Figure  2 ). The seroprevalence of anti-HEV (IgM+ and/or IgG+) was similar among at-flare samples in cases (36%; median ALT, 365 U/L) and matched controls (35%; median ALT, 29 U/L) (Supplementary Figure 1A) . The seroprevalence rates of anti-HEV were also similar among flare cases' postflare samples (31%; median ALT, 68 U/L) compared with matched postflare controls (29%; median ALT, 32 U/L) (Supplementary Figure  1B) . The odds of flaring were not significantly different between anti-HEV positive (IgG+ or IgM+) and anti-HEV negative (IgG-and IgM-) participants (OR, 1.3; 95% CI, 0.7-2.5) for the at-flare and matched samples (Supplementary Table 2 ). Similar results were found using postflare matched samples (OR, 1.2; 95% CI, 0.6-2.6).
Among 72 flare cases, seroprevalence of anti-HEV was similar pre-(29%), at-(36%), and postflare (31%) (Supplementary Figure 1C) , and seroprevalence of anti-HEV did not differ significantly between pre-vs at-(P = .45), pre-vs post-(P = .51), and at-vs postflare (P = .55) (Supplementary Table 3 ).
DISCUSSION
This study showed that acute HEV infection is a rare cause of spontaneous flares in persons with chronic hepatitis B in the United States and Canada. Initial screening of 600 serum samples randomly selected from eligible HBRN adult participants identified 10 subjects who were positive for anti-HEV IgM. Previous studies have noted variation in the performance of commercial assays for the detection of HEV-specific IgM [22] . There is no confirmatory assay for anti-HEV IgM antibodies, but false-positive rates are very low [22] . To further authenticate the 10 IgM-positive results, longitudinal analyses were performed to determine whether these anti-HEV IgM-positive measurements were biologically plausible. Of the 10 subjects, only 4 showed anti-HEV IgM declining and IgG increasing over time, providing a more stringent estimate of HEV IgM seroprevalence at 4/600 or 0.7%. This leaves 6 out of the 10 cases that were originally identified as anti-HEV IgM positive as unconfirmed. However, this may be overly stringent, as recent studies suggest that immunocompetent people infected with HEV in industrialized countries do not always develop a persistent humoral response to the virus and a sustained specific IgG response may be associated with repeated exposures [23] . Of the 10 anti-HEV IgM-positive subjects, only 1 showed elevated ALT just before seroconversion. This flare was transient and without jaundice. ALT elevation may have been missed in the other IgM-positive subjects if it was transient and normalized by the time of the subject's clinic visit. Asymptomatic infection with genotype 3 HEV is not uncommon, and studies of blood donors have detected HEV infection in the context of normal ALT levels [24] .
For 2 of the anti-HEV IgM-positive subjects, there was evidence for remote infection followed by reinfection. There is evidence in the literature of sero-reversion and reinfection [25] . More recently, anti-HEV IgG seroprevalence was found to be 6.0% (95% CI, 5.1%-6.9%) based on data from the NHANES 2009-2010 survey [26] . Differences in assay sensitivity between the 2 studies may partly account for the decline in HEV IgG seroprevalence, but analyses of samples from the different time periods using the same assay showed that anti-HEV prevalence was decreasing in the United States [27] . However, neither of the studies of NHANES participants used the Wantai commercial assay that was used in this study. Of commercial assays, several studies have found the Wantai anti-HEV IgG assay to have high sensitivity (>99%) and specificity (>96%) [28] [29] [30] [31] [32] [33] . A study that tested US blood donors for anti-HEV IgG using the Wantai ELISA found a seroprevalence of 18.8% (95% CI 17.0%-20.5%) in samples donated in 2006 and 2012 [34] . Compared with US blood donors, anti-HEV IgG prevalence among persons with chronic HBV in the HBRN Adult Cohort Study is significantly higher (28.5%; 95% CI, 24.9%-32.3%; P < .001). This difference could be due to HEV exposure in endemic regions of the world, because in our sampling of adult HBRN participants, 80.6% were born outside the United States or Canada. We found higher seroprevalence among persons born outside the United States and Canada, likely reflecting acquisition of acute HEV infection in areas of high endemicity and virus clearance before immigration. Additionally, higher seroprevalence was associated with lower education levels (less than a Bachelor's degree) among persons of Asian race. This may reflect higher risk of remote exposure to HEV (ie, before migration) among persons of lower socioeconomic status who immigrated from endemic regions. HEV RNA was not detected in any of the participants, consistent with the short duration of viremia during acute HEV infection and previous reports of low prevalence of HEV viremia in the United States-1:42 000 or 1:9500 based on screens of blood donors [35] or plasma donors [36] , respectively. HEV RNA was not measured in liver tissue or stool, neither of which was collected as part of the current observational study.
We did not find an association between ALT flares and previously undiagnosed HEV infection (as determined by seroconversion to anti-HEV IgG positive after the flare) among 72 flare cases. The lack of association between ALT flares and HEV infection in this study may be due to the small sample sizes that were available longitudinally among flare cases (Supplementary  Table 2 ) or the low prevalence of acute HEV infection in our study sample (ie, only 1 subject who experienced an ALT flare tested IgM+). A recent study showed that among patients with acute HEV infection at public hospitals and clinics in Hong Kong, those with underlying chronic hepatitis B had significantly worse disease outcomes and higher mortality [37] .
As discussed above, the seroprevalence of HEV-specific IgG was higher among persons of Asian race and persons born outside the United States or Canada. No information is available concerning whether these participants immigrated from regions of high HEV prevalence. It is interesting to speculate that they may have been exposed to acute (genotype 1 or 2) HEV infection and developed protective immunity before migration and thus be less likely to develop HEV infection following subsequent exposure to genotype 3 HEV in North America.
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